NCT01708902View on ClinicalTrials.gov

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

876

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

linagliptin2.5mg/metformin1000mg

linagliptin2.5mg/metformin1000mg BID

DRUG

linagliptin2.5mg/metformin1000mg

linagliptin2.5mg/metformin1000mg BID

DRUG

linagliptin 5mg

linagliptin 5mg once daily

DRUG

Metformin 500mg

Metformin 500mg BID

DRUG

linagliptin2.5mg/metformin500mg

linagliptin2.5mg/metformin500mg BID

DRUG

linagliptin2.5mg/metformin500mg

linagliptin2.5mg/metformin500mg BID

DRUG

linagliptin 5mg

linagliptin 5mg once daily

DRUG

Metformin 1000mg

Metformin 1000mg BID

Trial Locations (56)

Unknown

1288.18.86001 Boehringer Ingelheim Investigational Site, Beijing

1288.18.86002 Boehringer Ingelheim Investigational Site, Beijing

1288.18.86003 Boehringer Ingelheim Investigational Site, Beijing

1288.18.86004 Boehringer Ingelheim Investigational Site, Beijing

1288.18.86046 Boehringer Ingelheim Investigational Site, Beijing

1288.18.86019 Boehringer Ingelheim Investigational Site, Changchun

1288.18.86020 Boehringer Ingelheim Investigational Site, Changchun

1288.18.86028 Boehringer Ingelheim Investigational Site, Changsha

1288.18.86029 Boehringer Ingelheim Investigational Site, Changsha

1288.18.86050 Boehringer Ingelheim Investigational Site, Changsha

1288.18.86045 Boehringer Ingelheim Investigational Site, Chengdu

1288.18.86042 Boehringer Ingelheim Investigational Site, Chongqing

1288.18.86023 Boehringer Ingelheim Investigational Site, Dalian

1288.18.86009 Boehringer Ingelheim Investigational Site, Guangzhou

1288.18.86010 Boehringer Ingelheim Investigational Site, Guangzhou

1288.18.86012 Boehringer Ingelheim Investigational Site, Guangzhou

1288.18.86047 Boehringer Ingelheim Investigational Site, Haerbin

1288.18.86032 Boehringer Ingelheim Investigational Site, Hefei

1288.18.86016 Boehringer Ingelheim Investigational Site, Hengshui

1288.18.86017 Boehringer Ingelheim Investigational Site, Jinan

1288.18.86026 Boehringer Ingelheim Investigational Site, Lanzhou

1288.18.86039 Boehringer Ingelheim Investigational Site, Nanchang

1288.18.86035 Boehringer Ingelheim Investigational Site, Nanjing

1288.18.86036 Boehringer Ingelheim Investigational Site, Nanjing

1288.18.86034 Boehringer Ingelheim Investigational Site, Nanning

1288.18.86006 Boehringer Ingelheim Investigational Site, Shanghai

1288.18.86007 Boehringer Ingelheim Investigational Site, Shanghai

1288.18.86008 Boehringer Ingelheim Investigational Site, Shanghai

1288.18.86013 Boehringer Ingelheim Investigational Site, Shantou

1288.18.86022 Boehringer Ingelheim Investigational Site, Shenyang

1288.18.86014 Boehringer Ingelheim Investigational Site, Shijiazhuang

1288.18.86015 Boehringer Ingelheim Investigational Site, Shijiazhuang

1288.18.86038 Boehringer Ingelheim Investigational Site, Suzhou

1288.18.86049 Boehringer Ingelheim Investigational Site, Wuhan

1288.18.86033 Boehringer Ingelheim Investigational Site, Wuhu

1288.18.86024 Boehringer Ingelheim Investigational Site, Xi'an

1288.18.86025 Boehringer Ingelheim Investigational Site, Xi'an

1288.18.86030 Boehringer Ingelheim Investigational Site, Yueyang

1288.18.60004 Boehringer Ingelheim Investigational Site, Kelantan

1288.18.60003 Boehringer Ingelheim Investigational Site, Kuala Selangor

1288.18.60002 Boehringer Ingelheim Investigational Site, Malacca

1288.18.60005 Boehringer Ingelheim Investigational Site, Negeri Sembilan

1288.18.60007 Boehringer Ingelheim Investigational Site, Negeri Sembilan

1288.18.60001 Boehringer Ingelheim Investigational Site, Perak

1288.18.60006 Boehringer Ingelheim Investigational Site, Perak

1288.18.60008 Boehringer Ingelheim Investigational Site, Putrajaya

1288.18.63007 Boehringer Ingelheim Investigational Site, Cebu

1288.18.63003 Boehringer Ingelheim Investigational Site, Cebu City

1288.18.63002 Boehringer Ingelheim Investigational Site, Makati City

1288.18.63001 Boehringer Ingelheim Investigational Site, Manila

1288.18.63008 Boehringer Ingelheim Investigational Site, Quezon City

1288.18.63006 Boehringer Ingelheim Investigational Site, Surigao City

1288.18.63005 Boehringer Ingelheim Investigational Site, Tagum

1288.18.84003 Boehringer Ingelheim Investigational Site, Hanoi

1288.18.84001 Boehringer Ingelheim Investigational Site, Ho Chi Minh City

1288.18.84002 Boehringer Ingelheim Investigational Site, Ho Chi Minh City

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT01708902 - Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients | Biotech Hunter | Biotech Hunter